Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Mayne Pharma (ASX:MYX), a pharmaceutical company, became the subject of a broken takeover that Raper Capital sees as an opportunity. In July 2026, Raper Capital noted that 18 months earlier a sponsor-backed buyer had contracted to pay $7.40 per share for Mayne Pharma, and that after one of the ugliest broken deals in recent Australian corporate history, the shares traded far below that level, which it believes creates an attractive investment opportunity given the underlying business value. Mayne Pharma operates in the Healthcare sector within the Pharmaceuticals industry, and Thesis Tracker has captured 3 comments from 2 fund managers, including Raper Capital. Founded in 1845 and headquartered in Salisbury, Adelaide, Mayne Pharma develops, manufactures and sells branded and generic pharmaceutical products, focusing on women's health and dermatology in the United States, along with contract manufacturing services in Australia, and was the subject of a terminated acquisition by Cosette Pharmaceuticals.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Harvest Lane Asset Management and Raper Capital have invested in Mayne Pharma Group Ltd (ASX:MYX).
Raper Capital highlights the gap between the current share price and the $7.40 per share previously agreed by a sponsor-backed buyer, suggesting significant value in the underlying business.
Raper Capital notes the takeover collapsed in one of the ugliest broken deals in recent Australian corporate history, leaving uncertainty about how value will be realised.
Headquartered in Salisbury, Australia, and founded in 1845, Mayne Pharma Group Ltd. develops and manufactures proprietary and generic pharmaceutical products. The company operates through four segments: Generic Products, manufacturing and distributing generic and branded pharmaceuticals; Specialty Products, focusing on branded distribution; Metrics Contract Services, providing pharmaceutical contract services; and Mayne Pharma International, which manages sales, distribution, and third-party contract manufacturing in Australia. Mayne Pharma integrates these divisions to offer comprehensive pharmaceutical development and commercialization.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.